Trial Profile
Phase 3 study of tucatinib (ONT-380) in combination with Kadcyla in patients with breast cancer who have a history of central nervous system (CNS) metastases.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Tucatinib (Primary) ; Trastuzumab emtansine
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors Cascadian Therapeutics
- 09 Mar 2018 According to a Seattle Genetics media release, Cascadian Therapeutics has been acquired by Seattle Genetics, and this acquisition provides the Global Rights of Tucatinib to Seattle Genetics.
- 11 Dec 2015 New trial record
- 08 Dec 2015 According to Oncothyreon media release,company is planning to discuss about the designs of this trial, together with the overall registration strategy, with the regulatory authorities that includes the US FDA, in the first part of 2016.